{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T09:10:02Z","timestamp":1771233002472,"version":"3.50.1"},"reference-count":54,"publisher":"Elsevier BV","issue":"4-5","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","progcardvascdis.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.pcad.2018.01.003","type":"journal-article","created":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T17:57:32Z","timestamp":1515779852000},"page":"460-470","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Selection of P2Y 12 Inhibitor in Percutaneous Coronary Intervention and\/or Acute Coronary Syndrome"],"prefix":"10.1016","volume":"60","author":[{"given":"Udaya S.","family":"Tantry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliano P.","family":"Navarese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aung","family":"Myat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul A.","family":"Gurbel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcad.2018.01.003_bb0005","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1161\/CIRCULATIONAHA.109.853085","article-title":"Combination antithrombotic therapies","volume":"121","author":"Gurbel","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2018.01.003_bb0010","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1161\/CIRCULATIONAHA.111.031195","article-title":"Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents? Platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents","volume":"125","author":"Gurbel","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2018.01.003_bb0015","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1016\/j.jacc.2005.07.041","article-title":"Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING study","volume":"46","author":"Gurbel","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2018.01.003_bb0020","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1001\/jama.2010.181","article-title":"Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation","volume":"303","author":"Breet","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2018.01.003_bb0025","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1111\/j.1538-7836.2007.02609.x","article-title":"Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events","volume":"5","author":"Bonello","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.pcad.2018.01.003_bb0030","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0140-6736(13)61170-8","article-title":"Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study","volume":"382","author":"Stone","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2018.01.003_bb0035","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jcin.2009.10.024","article-title":"High residual platelet reactivity after clopidogrel: extent of coronary atherosclerosis and periprocedural myocardial infarction in patients with stable angina undergoing percutaneous coronary intervention","volume":"3","author":"Mangiacapra","year":"2010","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.pcad.2018.01.003_bb0040","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jcmg.2015.08.019","article-title":"Relationship between platelet reactivity and culprit lesion morphology: an assessment from the ADAPT-DES intravascular ultrasound substudy","volume":"9","author":"Yun","year":"2016","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.pcad.2018.01.003_bb0045","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/j.jacc.2014.01.069","volume":"63","author":"Kikkert","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2018.01.003_bb0050","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.jacc.2010.04.047","article-title":"Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate","volume":"56","author":"Bonello","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2018.01.003_bb0055","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1161\/01.CIR.0000072771.11429.83","article-title":"Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity","volume":"107","author":"Gurbel","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2018.01.003_bb0060","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1161\/01.CIR.0000157138.02645.11","article-title":"Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the clopidogrel loading with eptifibatide to arrest the reactivity of platelets (CLEAR PLATELETS) study","volume":"111","author":"Gurbel","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2018.01.003_bb0065","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.jacc.2005.01.030","article-title":"The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting","volume":"45","author":"Gurbel","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2018.01.003_bb0070","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.ahj.2010.12.011","article-title":"The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy","volume":"161","author":"Gurbel","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.pcad.2018.01.003_bb0075","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1001\/jama.2009.1232","article-title":"Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy","volume":"302","author":"Shuldiner","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2018.01.003_bb0085","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1056\/NEJMoa0909475","article-title":"Dose comparisons of clopidogrel and aspirin in acute coronary syndromes","volume":"363","author":"Mehta","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2018.01.003_bb0090","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S0140-6736(10)61088-4","article-title":"Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial","volume":"376","author":"Mehta","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2018.01.003_bb0095","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1016\/j.jacc.2011.08.007","article-title":"2011 ACCF\/AHA\/SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions","volume":"58","author":"Levine","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2018.01.003_bb0100","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1161\/CIR.0000000000000404","article-title":"2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease","volume":"134","author":"Levine","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2018.01.003_bb0105","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1161\/CIR.0000000000000133","article-title":"2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"130","author":"Amsterdam","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2018.01.003_bb0110","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1161\/CIR.0b013e3182742c84","article-title":"2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"127","author":"O'Gara","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2018.01.003_bb0115","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1517\/14656566.2012.704909","article-title":"Importance of potent P2Y(12) receptor blockade in acute myocardial infarction: focus on prasugrel","volume":"13","author":"Jeong","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.pcad.2018.01.003_bb0120","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1161\/CIRCULATIONAHA.107.740324","volume":"116","author":"Wiviott","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2018.01.003_bb0125","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.jacc.2012.02.026","volume":"59","author":"Trenk","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2018.01.003_bb0130","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2018.01.003_bb0135","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jacc.2012.03.030","article-title":"Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis","volume":"60","author":"Smith","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2018.01.003_bb0140","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0140-6736(08)60422-5","volume":"371","author":"Wiviott","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2018.01.003_bb0145","author":"U.S. Food and Drug Administration"},{"key":"10.1016\/j.pcad.2018.01.003_bb0150","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1056\/NEJMoa1205512","article-title":"Prasugrel versus clopidogrel for acute coronary syndromes without revascularization","volume":"367","author":"Roe","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2018.01.003_bb0155","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1001\/jama.2012.17312","article-title":"Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy","volume":"308","author":"Gurbel","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2018.01.003_bb0160","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1056\/NEJMoa1308075","article-title":"Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes","volume":"369","author":"Montalescot","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2018.01.003_bb0165","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1161\/CIRCULATIONAHA.109.912550","article-title":"Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET\/OFFSET study","volume":"120","author":"Gurbel","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2018.01.003_bb0170","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1161\/CIRCULATIONAHA.109.919456","article-title":"Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study","volume":"121","author":"Gurbel","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2018.01.003_bb0175","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2018.01.003_bb0180","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jacc.2010.01.062","article-title":"Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET\/OFFSET study","volume":"56","author":"Storey","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2018.01.003_bb0185","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1161\/CIRCULATIONAHA.111.047498","article-title":"Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial","volume":"124","author":"Mahaffey","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2018.01.003_bb0190","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2018.01.003_bb0195","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1185\/03007995.2014.880050","article-title":"Cangrelor: an emerging therapeutic option for patients with coronary artery disease","volume":"30","author":"Kubica","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.pcad.2018.01.003_bb0200","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1056\/NEJMoa0908628","article-title":"Platelet inhibition with cangrelor in patients undergoing PCI","volume":"361","author":"Harrington","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2018.01.003_bb0205","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa0908629","article-title":"Intravenous platelet blockade with cangrelor during PCI","volume":"361","author":"Bhatt","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2018.01.003_bb0210","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ahj.2011.11.001","article-title":"Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction","volume":"163","author":"White","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.pcad.2018.01.003_bb0215","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","article-title":"Effect of platelet inhibition with cangrelor during PCI on ischemic events","volume":"368","author":"Bhatt","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2018.01.003_bb0220","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/S0140-6736(13)61615-3","article-title":"Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data","volume":"382","author":"Steg","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2018.01.003_bb0225","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0140-6736(13)61451-8","article-title":"Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial","volume":"382","author":"Wiviott","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2018.01.003_bb0230","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1056\/NEJMoa1002358","article-title":"A prospective natural-history study of coronary atherosclerosis","volume":"364","author":"Stone","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2018.01.003_bb0235","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/eurheartj\/ehv531","article-title":"Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54","volume":"37","author":"Bonaca","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2018.01.003_bb0240","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1093\/eurheartj\/ehv573","article-title":"Deciding about prolonged ticagrelor therapy in coronary clot formers: an ongoing dilemma","volume":"37","author":"Gurbel","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2018.01.003_bb0245","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30\u202fmonths of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2018.01.003_bb0250","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1016\/j.jacc.2015.03.003","article-title":"Benefits and risks of extended duration dual antiplatelet therapy after PCI in patients with and without acute myocardial infarction","volume":"65","author":"Yeh","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2018.01.003_bb0255","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jacc.2016.07.791","article-title":"Platelet reactivity: journey to the end of the night","volume":"69","author":"Bonello","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2018.01.003_bb0260","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.2016.3775","article-title":"Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention","volume":"315","author":"Yeh","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2018.01.003_bb0265","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.resuscitation.2006.07.013","article-title":"Acute ST-elevation myocardial infarction after successful cardiopulmonary resuscitation","volume":"72","author":"Gorjup","year":"2007","journal-title":"Resuscitation"},{"key":"10.1016\/j.pcad.2018.01.003_bb0270","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ahj.2015.04.012","article-title":"Early P2Y12 inhibition in ST-segment elevation myocardial infarction: bridging the gap","volume":"170","author":"Alexopoulos","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.pcad.2018.01.003_bb0275","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S0140-6736(17)32155-4","article-title":"Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial","volume":"390","author":"Sibbing","year":"2017","journal-title":"Lancet"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062018300203?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062018300203?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T18:26:14Z","timestamp":1535135174000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062018300203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":54,"journal-issue":{"issue":"4-5","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S0033062018300203"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2018.01.003","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selection of P2Y12 Inhibitor in Percutaneous Coronary Intervention and\/or Acute Coronary Syndrome","name":"articletitle","label":"Article Title"},{"value":"Progress in Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcad.2018.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}